Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.317
NA - Nord America 2.592
AS - Asia 2.432
SA - Sud America 52
AF - Africa 19
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.549
RU - Federazione Russa 940
SG - Singapore 920
IE - Irlanda 896
IT - Italia 884
HK - Hong Kong 880
CN - Cina 298
ID - Indonesia 175
DE - Germania 124
GB - Regno Unito 104
SE - Svezia 95
FI - Finlandia 60
IN - India 55
NL - Olanda 47
BR - Brasile 38
ES - Italia 37
FR - Francia 27
CA - Canada 23
UA - Ucraina 21
JP - Giappone 20
MX - Messico 17
CH - Svizzera 15
TR - Turchia 13
PH - Filippine 12
VN - Vietnam 12
BE - Belgio 11
AU - Australia 10
DK - Danimarca 8
SA - Arabia Saudita 8
HR - Croazia 7
HU - Ungheria 7
CL - Cile 6
CO - Colombia 6
GR - Grecia 6
PL - Polonia 6
AT - Austria 5
CZ - Repubblica Ceca 5
IL - Israele 5
IR - Iran 5
KR - Corea 5
NP - Nepal 5
TN - Tunisia 5
MA - Marocco 4
RO - Romania 4
TH - Thailandia 4
TW - Taiwan 4
AZ - Azerbaigian 3
EG - Egitto 3
PK - Pakistan 3
ZA - Sudafrica 3
AM - Armenia 2
AR - Argentina 2
RS - Serbia 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
UG - Uganda 2
BG - Bulgaria 1
CR - Costa Rica 1
CY - Cipro 1
EU - Europa 1
GH - Ghana 1
JO - Giordania 1
LV - Lettonia 1
LY - Libia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 8.424
Salva come PNG Salva come JPEG
Città #
Hong Kong 876
Dublin 845
Singapore 819
Santa Clara 402
New York 390
Milan 229
Ashburn 186
Jakarta 171
Ann Arbor 124
Beijing 115
Turin 88
Frankfurt am Main 76
Seattle 56
Shanghai 51
Fairfield 46
Helsinki 42
Chandler 41
Rome 41
Desio 40
Boardman 34
London 31
São Paulo 26
Washington 25
Amsterdam 22
Houston 22
Los Angeles 22
Jacksonville 19
Princeton 18
Wilmington 18
Kilburn 17
Assago 16
Dearborn 16
Madrid 16
Cinisello Balsamo 14
Lappeenranta 14
Bologna 13
Cambridge 13
Phoenix 13
Woodbridge 13
Guadalajara 11
Mumbai 11
Nanjing 10
Naples 10
Altamura 9
Aurora 9
Lawrence 9
Manila 9
Moscow 9
Nuremberg 9
San Diego 9
Brussels 8
Carate Brianza 8
Chiswick 8
Paris 8
Debrecen 7
Hyderabad 7
Orbassano 7
Verona 7
Villongo 7
Zagreb 7
Changsha 6
Delhi 6
Kolkata 6
Montreal 6
Santa Monica 6
Brescia 5
Brugherio 5
Chengdu 5
Corsico 5
Dallas 5
Guangzhou 5
Istanbul 5
Melzo 5
Palermo 5
Rocca Canavese 5
San Jose 5
Shijiazhuang 5
Taiyuan 5
Tel Aviv 5
Veniano 5
Bari 4
Biratnagar 4
Catania 4
Como 4
Genoa 4
Hangzhou 4
Monza 4
Munich 4
Nantes 4
Ottawa 4
Padova 4
Perugia 4
Toronto 4
Torre Annunziata 4
Tunis 4
Xi'an 4
Aalst 3
Abbiategrasso 3
Afragola 3
Alatri 3
Totale 5.380
Salva come PNG Salva come JPEG
Nome #
Assessing eligibility for treatment in acute myeloid leukemia in 2023 291
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 206
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 157
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 157
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 135
Impact of serial echocardiography in the management of primary cardiac lymphoma 130
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 108
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 88
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 87
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 68
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 67
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 62
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 60
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 56
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 52
MIS-A: Beware of non-lymphoma 51
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 49
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 49
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 48
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 48
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 48
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 46
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 46
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 46
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 45
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 45
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 43
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 43
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 43
Arg expression studied in normal human leukocytes and in leukemic cells by RT-PCR 42
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 41
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 40
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 40
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 39
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 39
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 39
Fungal infections in hematologic neoplasms: Autopsy findings 39
Lymphoma’s last therapeutic option: Freeze it! 39
c-kit activating mutations and mast cell proliferation in human leukemia [4] 39
Detection by polymerase chain reaction of BCR/ ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation 38
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 38
Myeloma’s multiple morphologies 37
C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index 37
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 37
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 36
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 36
ACUTE PROMYELOCYTIC LEUKEMIA - COMPLETE REMISSION AND BONE-MARROW TRANSPLANTATION FOLLOW-UP MONITORED BY POLYMERASE CHAIN-REACTION 36
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 36
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 35
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 35
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 35
CLINICAL RELEVANCE OF RECURRENT ALLELE-SPECIFIC RECOMBINATION EXPRESSING THE WNT10BIVS1 ALLELE VARIANT IN ACUTE MYELOID LEUKEMIA 35
Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda” 35
LABNET AML: AN EFFICIENT NETWORK THAT CONNECTS HEMATOLOGY CENTERS AND LABORATORIES FOR A HIGH-LEVEL DIAGNOSTIC/PROGNOSTIC WORKUP OF AML 34
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 33
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 33
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 33
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 33
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 33
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL) 33
Detection of c-KIT antigen (CD117) and c-kit mRNA in acute leukemia 33
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 32
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 32
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 32
Gastrointestinal Kaposi's Sarcoma in a Woman with Selective IgA Deficiency and prior Immunosuppressive therapy for Idiopathic Thrombocitopenioc Purpura 32
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 32
Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases 32
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 32
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 31
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 31
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 31
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 31
Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience 31
Ibrutinib and its use in the treatment o chronic lymphocytic leukemia 31
Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era 31
IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB 31
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 31
Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial (Experimental Hematology & Oncology, (2021), 10, 1, (14), 10.1186/s40164-021-00210-9) 31
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 30
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 30
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19 30
High dose etoposide and cyclophosphamide (HD-VP/CTX) as salvage treatment for all patients 30
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 30
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 29
Prospective clinical study on extracorporeal photopheresis (ECP) as prophylaxis for chronic Graft Versus Host Disease (cGVHD) prophylaxis: an interim analysis 29
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 29
SEVERE HIV-RELATED THROMBOCYTOPENIA (HIV-REL TP) - COULD SPLENECTOMY IMPROVE SURVIVAL 29
Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment 29
Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial 29
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 29
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H 29
FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia 29
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience 28
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 28
Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia 28
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 28
Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens 28
Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia 28
Quantification of BCR/ABL transcript in mobilized cells of CML patients 28
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation 28
Totale 4.711
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202039 0 0 0 0 0 0 13 7 8 4 4 3
2020/2021141 3 3 40 14 15 11 12 12 14 6 3 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20253.714 545 1.184 457 439 783 295 11 0 0 0 0 0
Totale 9.397